DUBLIN, Dec. 13, 2023 /PRNewswire/ — The “Methylmalonic Acidaemia – Pipeline Insight, 2023” clinical trials has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Methylmalonic Acidaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The companies and academics are working to assess challenges and seek opportunities that could influence Methylmalonic Acidaemia R&D. The therapies under development are focused on novel approaches to treat/improve Methylmalonic Acidaemia.
Methylmalonic Acidaemia Emerging Drugs Chapters
This segment of the Methylmalonic Acidaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Methylmalonic Acidaemia Emerging Drugs
HST5040: HemoShear Therapeutics
HST5040 is an investigational oral small molecule therapy being developed by HemoShear to reduce the levels of toxins associated with methylmalonic acidemia (MMA) and propionic acidemia (PA), rare genetic disorders caused by the deficiency of certain enzymes required to metabolize amino acids. HST5040 is formulated for convenient daily administration at home as a liquid taken either orally or through a gastrostomy tube. The FDA has granted HST5040 Orphan Drug, Fast Track and Rare Pediatric Disease designations for the treatment of MMA and PA.Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Methylmalonic Acidemia.
Methylmalonic Acidaemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Methylmalonic Acidaemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Methylmalonic Acidaemia drugs.
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Methylmalonic Acidaemia drugs?
- How many Methylmalonic Acidaemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Methylmalonic Acidaemia?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Methylmalonic Acidaemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Methylmalonic Acidaemia and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- VectivBio AG
- CoA Therapeutics, Inc.
- HemoShear Therapeutics
- ModernaTX, Inc.
Key Products
- VB-1197
- BBP-671
- HST5040
- mRNA-3705
Methylmalonic Acidaemia: Therapeutic Assessment
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Methylmalonic Acidaemia Report Insights
- Methylmalonic Acidaemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/hidgfv
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo – https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
